Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Zhejiang Huahai Pharmaceutical Co., Ltd.
483
•Zhejiang Huahai Pharmaceutical Co., Ltd.•January 24, 2025

Zhejiang Huahai Pharmaceutical Co., Ltd. – FDA 483, Jan 24, 2025

Record Details

An FDA inspection conducted from January 16-17 and 20-24, 2025, at Zhejiang Huahai Pharmaceutical Co., Ltd. in Linhai, China, identified significant deficiencies in their drug manufacturing operations. The inspection, documented in an FDA Form 483, revealed multiple observations related to adherence to Good Manufacturing Practices (GMP).

Key issues included ineffective cleaning of non-dedicated equipment, with visible residues of multiple products found on surfaces intended for U.S. market drugs, and cleaning validation studies failing to adequately address hard-to-clean areas. Sterilization process validation for aseptic filling was found to be deficient, particularly concerning smoke studies for critical interventions. The firm also lacked adequate written procedures for production and process controls, impacting visual inspection qualification, tablet compression parameters, and process validation sampling.

Furthermore, the company failed to thoroughly investigate unexplained discrepancies, such as foreign matter in drug batches, out-of-specification dissolution results, out-of-trend impurities, and content uniformity failures. Deficiencies were noted in aseptic processing areas, including the unauthorized use of non-sterile tape to seal a critical gap in a Grade A filling line. Laboratory controls were inadequate, as analytical method validation studies lacked forced degradation for stability testing. Finally, the Quality Control unit's authority was compromised by a lack of audit trail reviews for production equipment and unverified manual data entry. Zhejiang Huahai Pharmaceutical is required to submit a comprehensive response outlining corrective actions to address these serious observations and ensure compliance with regulatory standards.

Company
Zhejiang Huahai Pharmaceutical Co., Ltd.
Inspection date
January 24, 2025
Product type
drugs
Office
Baltimore District Office
People
  • Jeffrey P. Raimondi (Consumer Safety Officer)
  • Justin A. Boyd (Research Specialist II)
View Company Profile

ID · 2926c83b-9c99-45b2-9b94-43a309b6c6a8

Other documents for Zhejiang Huahai Pharmaceutical Co., Ltd.
  • 483 - 2026-04-24April 24, 2026
  • 483 - 2025-04-16April 16, 2025
  • WARNING_LETTER - 2025-01-24January 24, 2025
  • 483 - 2019-06-28June 28, 2019
  • 483 - 2019-05-31May 31, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Huahai Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.